Research progress on liquid biopsy in pancreatic cancer

doi:10.3760/cma.j.issn.1673-422X.2018.03.012

Abstract

Abstract: Liquid biopsy is a kind of popular and emerging pathological detection technology, which mainly includes the detection of circulating tumor cells, circulating tumor DNA and exosome. Recent studies show that liquid biopsy not only plays a potential advantage in early diagnosis of pancreatic cancer, but also has some guiding significance for prognosis and recurrence monitoring of pancreatic cancer.

Key words: Pancreatic neoplasms, Neoplasm circulating cells, Circulating tumor DNA, Liquid biopsy, Exosome

Li Zhijian, He De. Research progress on liquid biopsy in pancreatic cancer[J]. Journal of International Oncology, 2018, 45(3): 180-182.

References

［1］ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017［J］. CA Cancer J Clin, 2017, 67(1): 7-30. DOI: 10.3322/caac.21387. ［2］ Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States［J］. Cancer Res, 2014, 74(11): 29132921. DOI: 10.1158/00085472.CAN140155. ［3］ Seufferlein T, Mayerle J. Pancreatic cancer in 2015: precision medicine in pancreatic cancer—fact or fiction?［J］. Nat Rev Gastroenterol Hepatol, 2016, 13(2): 74-75. DOI: 10.1038/nrgastro.2015.215. ［4］ Millner LM, Strotman LN. The future of precision medicine in oncology［J］. Clin Lab Med, 2016, 36(3): 557-573. DOI: 10.1016/j.cll.2016.05.003. ［5］ Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies［J］. Somatic Cell Genet, 1979, 5(6): 957-971. ［6］ Zhang Q, Chen S, Zeng L, et al. New developments in the early diagnosis of pancreatic cancer［J］. Expert Rev Gastroenterol Hepatol, 2017, 11(2): 149-156. DOI: 10.1080/17474124.2017.1271323. ［7］ Poruk KE, Gay DZ, Brown K, et al. The clinical utility of CA 199 in pancreatic adenocarcinoma: diagnostic and prognostic updates［J］. Curr Mol Med, 2013, 13(3): 340-351. ［8］ Chang JC, Kundranda M. Novel diagnostic and predictive biomarkers in pancreatic adenocarcinoma［J］. Int J Mol Sci, 2017, 18(3): E667. DOI: 10.3390/ijms18030667. ［9］ Kim YJ, Koh HK, Chie EK, et al. Change in carbohydrate antigen 199 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy［J］. Int J Clin Oncol, 2017, 22(6): 1069-1075. DOI: 10.1007/s10147-017-1129. ［11］ Kulemann B, Pitman MB, Liss AS, et al. Circulating tumor cells found in patients with localized and advanced pancreatic cancer［J］. Pancreas, 2015, 44(4): 547-550. DOI: 10.1097/MPA.0000000000000324. ［12］ Liu H, Sun B, Wang S, et al. Circulating tumor cells as a biomarker in pancreatic ductal adenocarcinoma［J］. Cell Physiol Biochem, 2017, 42(1): 373-382. DOI: 10.1159/000477481. ［13］ Ankeny JS, Court CM, Hou S, et al. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer［J］. Br J Cancer, 2016, 114(12): 1367-1375. DOI: 10.1038/bjc.2016.121. ［14］ Tien YW, Kuo HC, Ho BI, et al. A high circulating tumor cell count in portal vein predicts liver metastasis from periampullary or pancreatic cancer: a high portal enous CTC count predicts liver metastases［J］. Medicine (Baltimore), 2016, 95(16): e3407. DOI: 10.1097/MD.0000000000003407. ［15］ Arnoletti JP, Zhu X, Almodovar AJ, et al. Portal venous blood circulation supports immunosuppressive environment and pancreatic cancer circulating tumor cell activation［J］. Pancreas, 2017, 46(1): 116-123. DOI: 10.1097/MPA.0000000000000667. ［16］ Poruk KE, Valero 3rd, Saunders T, et al. Circulating tumor cell phenotype predicts recurrence and survival in pancreatic adenocarcinoma［J］. Ann Surg, 2016, 264(6): 1073-1081. DOI: 10.1097/SLA.0000000000001600. ［17］ Mandel P, Metais P. Les acides nucleiques du plasma sanguin chez I′homme［J］. Cr Acad Sci Paris, 1948, 142(3-4): 241-243. ［18］高芃, 李金明. 循环肿瘤DNA与肿瘤精准治疗［J］. 实用医院临床杂志, 2016, 13(3): 16. DOI: 10.3969/j.issn.16726170.2016.03.001. ［19］ Henriksen SD, Madsen PH, Larsen AC, et al. Cellfree DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma［J］. Clin Epigenetics, 2016, 8: 117. DOI: 10.1186/s1347801602862. ［20］ Henriksen SD, Madsen PH, Larsen AC, et al. Promoter hypermethylation in plasmaderived cellfree DNA as a prognostic marker for pancreatic adenocarcinoma staging［J］. Int J Cancer, 2017, 141(12): 24892497. DOI: 10.1002/ijc.31024. ［21］ Creemers A, Krausz S, Strijker M, et al. Clinical value of ctDNA in upperGI cancers: a systematic review and metaanalysis［J］. Biochim Biophys Acta, 2017, 1868(2): 394-403. DOI: 10.1016/j.bbcan.2017.08.002. ［22］ Singh N, Gupta S, Pandey RM, et al. High levels of cellfree circulating nucleic acids in pancreatic cancer are associated with vascular encasement, metastasis and poor survival［J］. Cancer Invest, 2015, 33(3): 78-85. DOI: 10.3109/07357907.2014.1001894. ［23］ Pietrasz D, Pécuchet N, Garlan F, et al. Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker［J］. Clin Cancer Res, 2017, 23(1): 116-123. DOI: 10.1158/1078-0432.CCR-16-0806. ［24］ Pan BT, Teng K, Wu C, et al. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes［J］. J Cell Biol, 1985, 101(3): 942948. ［25］ Steinbichler TB, Dudás J, Riechelmann H, et al. The role of exosomes in cancer metastasis［J］. Semin Cancer Biol, 2017, 44: 170-181. DOI: 10.1016/j.semcancer.2017.02.006. ［26］ Whiteside TL. Tumorderived exosomes and their role in cancer progression［J］. Adv Clin Chem, 2016, 74: 103-141. DOI: 10.1016/bs.acc.2015.12.005. ［27］ Melo SA, Luecke LB, Kahlert C, et al. Glypican1 identifies cancer exosomes and detects early pancreatic cancer［J］. Nature, 2015, 523(7559): 177-182. DOI: 10.1038/nature14581. ［28］ Lai X, Wang M, Mcelyea SD, et al. A microRNA signature in circulating exosomes is superior to exosomal glypican1 levels for diagnosing pancreatic cancer［J］. Cancer Lett, 2017, 393: 86-93. DOI: 10.1016/j.canlet.2017.02.019.

[1]	Liu Bohan, Huang Junxing. Research progress of liquid biopsy technology in esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(2): 105-108.
[2]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.
[3]	Zhang Yuan, Bai Zhiyu, Li Qi, Feng Qinmei. Current status of research on exosomes in malignancies [J]. Journal of International Oncology, 2023, 50(8): 484-488.
[4]	Kui Guoju, Huang Jiangbin, Zhang Wenhua, Yang Limin. Effect of regional lymph node diameter on postoperative recurrence in pancreatic cancer patients [J]. Journal of International Oncology, 2023, 50(10): 608-613.
[5]	Li Hongyu, Wu Xinlin. Exosomes and liver metastasis of colorectal cancer [J]. Journal of International Oncology, 2022, 49(12): 749-753.
[6]	Wang Wenhao, Sun Xirui, Liu Jin, Sun Xiumei. Role of cancer-associated fibroblasts in the development and progression of breast cancer [J]. Journal of International Oncology, 2022, 49(10): 615-618.
[7]	Zhang Wanchen, Xu Jiajie, Zhang Lizhuo, Ge Minghua. Clinical significance of exosomal-circRNA in tumor diagnosis and treatment [J]. Journal of International Oncology, 2021, 48(9): 549-552.
[8]	Zhuang Weitao, Qiao Guibin. Research and application of liquid biopsy based on epigenetic markers in the diagnosis and treatment of solid tumors [J]. Journal of International Oncology, 2021, 48(6): 358-361.
[9]	Yan Zhiying, Mao Yifeng, Zhu Yingwei, Xu Kequn. Role of heterogeneity of cancer-associated fibroblasts in targeted therapy of pancreatic cancer [J]. Journal of International Oncology, 2021, 48(5): 308-312.
[10]	Zhong Yang, He Miao, Liu Zhi, Chen Jianyu, Zhang Guangnian, Qin Long, Li Ting, Li Jianshui. Effects of Ophiopogon D combined with cyclooxygenase-2 silencing on proliferation, migration and invasion of human pancreatic cancer BxPC-3 cells [J]. Journal of International Oncology, 2021, 48(10): 583-590.
[11]	Li Keke, Kong Panpan, Yi Chao, Wang Xiyan, Yan Dong. Expression of lymphoid enhancer factor-1 in pancreatic ductal adenocarcinoma and its effect on prognosis [J]. Journal of International Oncology, 2021, 48(10): 608-613.
[12]	Chen Xiaoxu, Yu Yang, Zhang Tianxue. A prognostic risk assessment model for pancreatic cancer established based on immune-related lncRNAs [J]. Journal of International Oncology, 2020, 47(8): 472-479.
[13]	Du Mingli, Li Guixiang, Wu Wenjuan, Zhao Lei. Application of circulating tumor DNA in targeted therapy and immunotherapy of metastatic melanoma [J]. Journal of International Oncology, 2020, 47(6): 381-384.
[14]	Tian Linghan, Zhu Ling, Liu Xin, Ye Jingwen, He Jiahui, Wang Xicai. Level of peripheral blood circulating tumor cells in lung cancer patients detected by CI-101 and its clinical significance [J]. Journal of International Oncology, 2020, 47(4): 199-204.
[15]	Tian Chunfang, Sha Dan. Zinc finger proteins and digestive system cancers [J]. Journal of International Oncology, 2020, 47(2): 115-118.